Evidence map›Paper›PMID 38335302›Full record

ArticleCancer research communications2024

Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer.

Laia Gorchs, Carlos Fernández-Moro, Ebba Asplund, Marlies Oosthoek, Martin Solders, Poya Ghorbani, Ernesto Sparrelid, Elena Rangelova, Matthias J Löhr, Helen Kaipe

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. CD39 on CD8European journal of immunology · 2026
    Review
  2. Antigen-specific CD8British journal of cancer · 2026
    Article
  3. Targeting CD39 as a Therapeutic for Cancer Immunotherapy.Expert reviews in molecular medicine · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Terminally exhausted CD8Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Laia GorchsDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-8766-6686
Carlos Fernández-MoroDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6863-5959
Ebba AsplundDepartment of Upper GI, C1:77 Karolinska Comprehensive Cancer Center, Stockholm, Sweden.ORCID 0000-0002-7649-7901
Marlies OosthoekDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0000-8714-4944
Martin SoldersDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6951-1958
Poya GhorbaniDepartment of Upper GI, C1:77 Karolinska Comprehensive Cancer Center, Stockholm, Sweden.ORCID 0000-0003-2102-7168
Ernesto SparrelidDepartment of Upper GI, C1:77 Karolinska Comprehensive Cancer Center, Stockholm, Sweden.ORCID 0000-0003-0259-8328
Elena RangelovaDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-3844-7265
Matthias J LöhrDepartment of Upper GI, C1:77 Karolinska Comprehensive Cancer Center, Stockholm, Sweden.ORCID 0000-0002-7647-198X
Helen KaipeDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7391-1137
Karolinska Institutet · SEKarolinska University Hospital · SESahlgrenska University Hospital · SE

Funding

Cancerföreningen i Stockholm (Cancer Society in Stockholm) 201152Cancerföreningen i Stockholm (Cancer Society in Stockholm) 221173Insamlingsstiftelsen Cancer- och Allergifonden (Cancer and Allergy Fund) 10388Insamlingsstiftelsen Cancer- och Allergifonden (Cancer and Allergy Fund) 10679Ruth och Richard Julins Stiftelse (Ruth and Richard Julin Foundation) 2022-00285Swedish Cancer Foundation 20 1162 PjF
6 · The paper itself

Abstract

In pancreatic ductal adenocarcinoma, the infiltration of CD8+ T cells within the tumor microenvironment correlates with a favorable prognosis. However, a significant proportion of tumor-infiltrating T cells become trapped within the desmoplastic stroma and lack tumor reactivity. Here, we explored different T-cell subsets in pancreatic tumors and adjacent tissues. We identified a subset of CD8+ T cells, double positive (DP) for CD39 and CD103 in pancreatic tumors, which has recently been described to display tumor reactivity in other types of solid tumors. Interestingly, DP CD8+ T cells preferentially accumulated in central tumor tissues compared with paired peripheral tumor and adjacent non-tumor tissues. Consistent with an antigen encounter, DP CD8+ T cells demonstrated higher proliferative rates and displayed an exhausted phenotype, characterized by elevated expression of PD-1 and TIM-3, compared with CD39-CD103- CD8+ T cells. In addition, DP CD8+ T cells exhibited higher expression levels of the tissue trafficking receptors CCR5 and CXCR6, while displaying lower levels of CXCR3 and CXCR4. Importantly, a high proportion of DP CD8+ T cells is associated with increased patient survival. These findings suggest that DP CD8+ T cells with a phenotype reminiscent of that of tumor-reactive T cells are present in pancreatic tumors. The abundance of DP CD8+ T cells could potentially aid in selecting patients for pancreatic cancer immunotherapy trials. SIGNIFICANCE: Patients with pancreatic cancer with a high proportion of CD39+CD103+ CD8+ T cells exhibiting a tumor-reactive phenotype have improved survival rates, suggesting their potential utility in selecting candidates for immunotherapy trials.

Indexed as

CD8-Positive T-LymphocytesPancreatic NeoplasmsHumansPhenotypePrognosisT-Lymphocyte SubsetsTumor Microenvironment

Identifiers

PMID38335302
PMCPMC10875982
OpenAlexW4391677791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.